Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690595 · ClinicalTrials.gov registry record · Phase 1
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
A Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by PeproMene Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04690595 is a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by PeproMene Bio. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04690595, a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by PeproMene Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Conditions Studied
Interventions
- BIOLOGICAL BAFFR-CAR T cells
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2027-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04690595
The ClinicalTrials.gov registry entry for NCT04690595 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PeproMene Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which BAFFR-CAR T cells is the first listed.
NCT04690595 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04690595 about?
NCT04690595 is a clinical study titled "BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL". A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
What is the current status of trial NCT04690595?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-05-18. Estimated completion is 2027-11-18.
What conditions does trial NCT04690595 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04690595?
The interventions under investigation include: BAFFR-CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04690595?
This trial is sponsored by PeproMene Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04690595 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.